Dosing down with biologic therapies: a systematic review and clinicians’ perspective

Christopher J. Edwards¹, Bruno Fautrel²,³, Hendrik Schulze-Koops⁴, Tom W.J. Huizinga⁵ and Klaus Kruger⁶

The author affiliations in this paper have been corrected online. The correct affiliation numbers are also given above.

¹Musculoskeletal Research Unit, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK, ²Pierre et Marie Curie University Paris 6, Sorbonne Universités, Pierre Louis Institute of Epidemiology and Public Health, Paris, GRC-08 (EEMOIS), ³APHP, Rheumatology Department, Pitié Salpêtrière Hospital, Paris, F-75013, France, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universität, Munich, Germany, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, C1-41, The Netherlands and ⁶Rheumatologisches Schwerpunktzentrum, Munich, Germany

Correspondence to: Christopher J. Edwards, Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, Mailpoint 63, G Level, West Wing Southampton General Hospital Southampton, SO16 6YD, UK.
E-mail: cedwards@soton.ac.uk